AstraZeneca purchases US facility to support biologics manufacturing capabilities


12-10-2016

AstraZeneca announced that it has purchased a biologics manufacturing facility in Longmont, Colorado, USA, from Amgen Inc. This facility will be used to support AstraZeneca’s existing operations at its nearby Boulder site also purchased from Amgen in September of 2015.

Add This Share Buttons

Darren Dasburg, Boulder Manufacturing Center Site Director, AstraZeneca, said: “The Longmont facility adds to our expanding biologics commercial manufacturing capabilities as we prepare for our exciting future biologic medicines. Integrating this site into our existing operations network will provide AstraZeneca and MedImmune, our global biologics research and development arm, with flexible biological manufacturing capacity to quickly bring new innovative treatments to patients.”

The site will be staffed over time and according to business needs as the company’s pipeline matures and expansions are deemed necessary.



*******
   
CONTACTS

Media Inquiries
Abigal Bozarth                        
+1 302 885 2677

___________________________________

 

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

AstraZeneca